Optimizing the Diagnostic Algorithm for Systemic Autoimmune Diseases: Navigating ANA/anti-ENA Discordance

Abstract

The diagnostic workup for systemic autoimmune diseases typically follows a sequential algorithm, beginning with antinuclear antibody (ANA) screening via indirect immunofluorescence (IIF) followed by specific anti-extractable nuclear antigen (anti-ENA) testing. Despite its robustness, clinicians frequently encounter biological discrepancies—such as ANA-positive/anti-ENA-negative or ANA-negative/anti-ENA-positive results—that can lead to diagnostic uncertainty, unnecessary medical costs, or delayed treatment. Objectives: This review aims to analyze the technical and biological mechanisms underlying these discrepancies and proposes an optimized, pragmatic decision-making framework based on clinical probability. Methods: We examine the foundations of the traditional diagnostic algorithm, focusing on the sensitivity and specificity of IIF on HEp-2 cells compared to targeted ENA panels. Technical factors such as antigen solubility ("wash-out" effect), substrate variation, and the clinical significance of specific patterns (e.g., AC-2/anti-DFS70) are evaluated. Results: ANA-positive/anti-ENA-negative results often stem from low-titer non-specific positivity, targets not included in standard panels, or pre-clinical phases. Conversely, ANA-negative/anti-ENA-positive cases, though rarer, are clinically critical and often involve specific antibodies like anti-SSA/Ro, which may be undetectable by standard IIF due to antigen accessibility or technical interference. Conclusion: Effective diagnosis requires moving beyond strict algorithmic adherence toward a "nuanced interpretation" model. An optimized approach integrates IIF titers and staining patterns with pre-test clinical probability. Ultimately, clinical suspicion must take precedence over discordant laboratory results to prevent under-diagnosis in symptomatic patients and over-diagnosis in asymptomatic individuals.